Mirum Pharmaceuticals
MIRM
187 hedge funds and large institutions have $1.49B invested in Mirum Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 69 increasing their positions, 52 reducing their positions, and 16 closing their positions.
181% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 16
33% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 52
20% more call options, than puts
Call options by funds: $4.32M | Put options by funds: $3.59M
18% more funds holding
Funds holding: 159 → 187 (+28)
4% less capital invested
Capital invested by funds: $1.55B → $1.49B (-$54.5M)
19.4% less ownership
Funds ownership: 127.77% → 108.37% (-19%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.7M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$15.1M |
| 4 |
BlackRock
New York
|
+$10.5M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$69.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$39.2M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$24.2M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$16.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.31M |
MIRM Hedge Fund Activity: Q4 2023 in Review
187 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q4 2023, worth a combined $1.49B — down 3.5% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new MIRM positions and 16 closed out — a net gain of 29 holders — while 69 added to existing stakes and 52 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $34.3M. The largest seller was NEA Management Company, exiting entirely with an estimated $69.1M sold.
- 187 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q4 2023, up from 159 in Q3 2023.
- Funds reported $1.49B of Mirum Pharmaceuticals stock for Q4 2023, down 3.5% quarter-over-quarter.
- 45 funds opened new Mirum Pharmaceuticals positions in Q4 2023 and 16 closed out, a net change of +29 holders.
- The largest Mirum Pharmaceuticals buyer in Q4 2023 was T. Rowe Price Associates, an estimated $34.3M added.
- The largest Mirum Pharmaceuticals seller in Q4 2023 was NEA Management Company, an estimated $69.1M sold.
Based on aggregated 13F filings for Q4 2023.